HK1202432A1 - Pluripotent germ layer origin antigen presenting cancer vaccine - Google Patents

Pluripotent germ layer origin antigen presenting cancer vaccine Download PDF

Info

Publication number
HK1202432A1
HK1202432A1 HK15103009.6A HK15103009A HK1202432A1 HK 1202432 A1 HK1202432 A1 HK 1202432A1 HK 15103009 A HK15103009 A HK 15103009A HK 1202432 A1 HK1202432 A1 HK 1202432A1
Authority
HK
Hong Kong
Prior art keywords
antigen presenting
cancer vaccine
germ layer
pluripotent germ
presenting cancer
Prior art date
Application number
HK15103009.6A
Other languages
English (en)
Chinese (zh)
Inventor
Andrew CORNFORTH
Robert DILLMAN
Original Assignee
Caladrius Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caladrius Biosciences, Inc. filed Critical Caladrius Biosciences, Inc.
Publication of HK1202432A1 publication Critical patent/HK1202432A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
HK15103009.6A 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine HK1202432A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261594304P 2012-02-02 2012-02-02
US61/594,304 2012-02-02
PCT/US2013/024123 WO2013116505A1 (en) 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine

Publications (1)

Publication Number Publication Date
HK1202432A1 true HK1202432A1 (en) 2015-10-02

Family

ID=48905824

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15103009.6A HK1202432A1 (en) 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine
HK15110097.4A HK1209455A1 (en) 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15110097.4A HK1209455A1 (en) 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine

Country Status (13)

Country Link
US (1) US20150064217A1 (https=)
EP (1) EP2809775B1 (https=)
JP (1) JP2015506698A (https=)
KR (1) KR20140143361A (https=)
CN (1) CN104540937A (https=)
AU (1) AU2013215116A1 (https=)
CA (1) CA2863653A1 (https=)
GB (1) GB2512558A (https=)
HK (2) HK1202432A1 (https=)
IL (1) IL233928A0 (https=)
NZ (1) NZ628292A (https=)
SG (1) SG11201404543UA (https=)
WO (2) WO2013116541A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103599528B (zh) * 2013-12-04 2015-08-05 深圳市合一康生物科技股份有限公司 人树突状细胞疫苗的制备方法
RU2684911C2 (ru) 2014-10-07 2019-04-16 Ситлимик Инк. Пептид, полученный из hsp70, фармацевтическая композиция для лечения или профилактики рака, содержащая такой пептид, индуктор иммунного ответа и способ получения антиген-презентирующей клетки
AU2017342189B2 (en) 2016-10-11 2023-09-21 Nec Corporation Medicine
JPWO2018131659A1 (ja) * 2017-01-11 2019-12-12 国立研究開発法人国立がん研究センター 免疫療法剤
AU2018222737B2 (en) * 2017-02-17 2021-03-25 Aivita Biomedical, Inc. Methods to enhance tumor immunogenicity and compositions for autologous cancer immunotherapeutic products using modified tumor cells and modified dendritic cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140796A0 (en) * 2001-01-08 2002-02-10 Hadasit Med Res Service An autologous anti-cancer vaccine
CN1636229B (zh) * 2001-09-06 2012-12-19 西北生物治疗药物公司 引发单核树突细胞和t细胞th-1应答的组合物和方法
JP5623004B2 (ja) * 2004-10-25 2014-11-12 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 熱ショックをかけたメラノーマ細胞体が装填された樹状細胞
KR101374091B1 (ko) * 2005-07-29 2014-03-17 프로비던스 헬스 앤드 서비시즈, 오레곤 수포에 담긴 불완전 리보솜 생성물（ＤＲｉｂｂｌｅ） 및 면역 반응을 자극하기 위해 이를 이용하는 방법
WO2008039974A2 (en) * 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US20090041792A1 (en) * 2007-07-19 2009-02-12 Istituto Superiore Di Sanita Dendritic cells, uses therefor, and vaccines and methods comprising the same

Also Published As

Publication number Publication date
HK1209455A1 (en) 2016-04-01
JP2015506698A (ja) 2015-03-05
IL233928A0 (en) 2014-09-30
EP2809775B1 (en) 2018-06-13
NZ628292A (en) 2016-09-30
KR20140143361A (ko) 2014-12-16
US20150064217A1 (en) 2015-03-05
EP2809775A4 (en) 2015-07-01
CN104540937A (zh) 2015-04-22
CA2863653A1 (en) 2013-08-08
SG11201404543UA (en) 2014-08-28
GB201414403D0 (en) 2014-10-01
GB2512558A (en) 2014-10-01
EP2809775A1 (en) 2014-12-10
AU2013215116A1 (en) 2014-08-21
WO2013116505A1 (en) 2013-08-08
WO2013116541A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
HK1213924A1 (zh) 用於治療癌症的抗kir和抗ctla-4抗體組合
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
PH12019500193A1 (en) Chimeric antigen receptors targeting bcma and methods of use thereof
MX2024010239A (es) Receptores de antigenos quimericos dirigidos a bcma y metodos de uso de estos.
PH12016501384B1 (en) Human antibodies to pd-l1
EP2566890A4 (en) ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE
EP4417263A3 (en) Cd3 binding antibodies
EP4245376A3 (en) Antibody molecules to pd-l1 and uses thereof
PH12015500196A1 (en) Methods of treating a tauopathy
WO2013176916A8 (en) Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
EP4249065A3 (en) Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
BR112015003757A2 (pt) anticorpos e vacinas para uso no tratamento de cânceres de ror1 e inibição de metástase
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
EP3107565A4 (en) Methods, compositions and kits for cell specific modulation of target antigens
MX385933B (es) Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer.
PL2917229T3 (pl) Przeciwciała i ich fragmenty aktywowane przeciwko domenie alfa-3 białka HLA-G, sposoby i środki ich wytwarzania oraz ich zastosowania
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
MX2014014376A (es) Anticuerpos de anti-biotina y metodos de uso.
HK1202432A1 (en) Pluripotent germ layer origin antigen presenting cancer vaccine
AU2012323781A8 (en) Antibodies to CD1d
HK1201176A1 (en) Antigen presenting cancer vaccine
EP3060648A4 (en) Systems, devices and methods for microfluidic culturing, manipulation and analysis of tissues and cells
WO2011153431A3 (en) Peripheral blood sparc antibodies and uses thereof
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
WO2013082249A3 (en) Compositions and methods for prostate cancer analysis